መነሻ › ስቴቶቲክ የጉበት በሽታ › Texas
በTexas ለስቴቶቲክ የጉበት በሽታ የሚደረጉ ክሊኒካዊ ጥናቶች
ለስቴቶቲክ የጉበት በሽታ የሚደረጉ 20 ጥናቶች በTexas ባሉ ቦታዎች ተሳታፊዎችን እየፈለጉ ነው።
በTexas ውስጥ ያሉ ከተሞች
- San Antonio17 ጥናቶች
- Houston13 ጥናቶች
- Austin13 ጥናቶች
- Dallas9 ጥናቶች
- Brownsville7 ጥናቶች
- Round Rock7 ጥናቶች
- Fort Worth6 ጥናቶች
- Sugar Land6 ጥናቶች
- Arlington6 ጥናቶች
- Waco6 ጥናቶች
- Grand Prairie5 ጥናቶች
- Carrollton4 ጥናቶች
- Pasadena4 ጥናቶች
- Edinburg4 ጥናቶች
- The Woodlands4 ጥናቶች
- Lewisville3 ጥናቶች
- League City3 ጥናቶች
- Corpus Christi3 ጥናቶች
Official study text (English)
A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
- GSK Investigational Site, Arlington
- GSK Investigational Site, Austin
- GSK Investigational Site, Bellaire
- እና 5 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ ከ18 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ30 ሴፕቴ 2026 · NCT07704892A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
- GSK Investigational Site, Arlington
- GSK Investigational Site, Austin
- GSK Investigational Site, Bellaire
- እና 4 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ ከ18 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ30 ሴፕቴ 2026 · NCT07701993A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD
- American Research Corporation, Austin
- Advanced Medical Trials, Georgetown
- American Research Corporation at The Texas Liver Institute, San Antonio
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ ከ18 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ29 ሴፕቴ 2026 · NCT07527910A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
- American Research Corporation, Austin
- Pinnacle Clinical Research - Austin, Austin
- Methodist Dallas Medical Center, Dallas
- እና 5 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ ከ18 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ25 ሴፕቴ 2026 · NCT05519475A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- IMA Clinical Research Austin, Austin
- American Research Corporation, Austin
- Pinnacle Clinical Research, Austin
- እና 26 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ22 ሴፕቴ 2026 · NCT07165028A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Akero Clinical Study Site, Arlington
- Akero Clinical Study Site, Austin
- Akero Clinical Study Site, Austin
- እና 28 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ ከ18 እስከ 80 · ሁሉም ጾታዎች · የተሻሻለው በ21 ሴፕቴ 2026 · NCT06528314A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
- GSK Investigational Site, Austin
- GSK Investigational Site, Austin
- GSK Investigational Site, Brownsville
- እና 12 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ ከ18 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ17 ሴፕቴ 2026 · NCT07221188A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Pinnacle Clinical Research, Austin
- Bellaire Clinical Research, Bellaire
- South Texas Research Institute (STRI) - Brownsville, Brownsville
- እና 14 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ ከ18 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ9 ሴፕቴ 2026 · NCT07288138A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- 89bio Clinical Study Site, Amarillo
- 89bio Clinical Study Site, Austin
- 89bio Clinical Study Site, Austin
- እና 30 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ ከ18 እስከ 80 · ሁሉም ጾታዎች · የተሻሻለው በ3 ሴፕቴ 2026 · NCT06318169A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- 89bio Clinical Study Site, Amarillo
- 89bio Clinical Study Site, Austin
- 89bio Clinical Study Site, Austin
- እና 21 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ ከ18 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ3 ሴፕቴ 2026 · NCT06419374Quantifying Hepatic Mitochondrial Fluxes in Humans
- Texas Diabetes Institute - University Health System, San Antonio
- University of Texas Health Science Center at San Antonio, San Antonio
ተሳታዮችን በመፈለግ ላይደረጃ 4
እድሜ ከ18 እስከ 80 · ሁሉም ጾታዎች · የተሻሻለው በ17 ኦገስ 2026 · NCT05305287A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
- GSK Investigational Site, Arlington
- GSK Investigational Site, Austin
- GSK Investigational Site, Dallas
- እና 4 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ ከ18 እስከ 70 · ሁሉም ጾታዎች · የተሻሻለው በ3 ኦገስ 2026 · NCT06613698A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
- GSK Investigational Site, Arlington
- GSK Investigational Site, Austin
- GSK Investigational Site, Austin
- እና 16 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ ከ18 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ27 ጁላይ 2026 · NCT07221227A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
- GSK Investigational Site, Austin
- GSK Investigational Site, Austin
- GSK Investigational Site, Austin
- እና 10 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ ከ18 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ8 ጁላይ 2026 · NCT06920043A Study of Efimosfermin Alfa in Adults With Hepatic Impairment
- GSK Investigational Site, San Antonio
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ ከ18 እስከ 70 · ሁሉም ጾታዎች · የተሻሻለው በ9 ጁን 2026 · NCT07358546Evaluating the Pharmacokinetics and Safety of Miricorilant
- Site# 433, San Antonio
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ ከ18 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ26 ሜይ 2026 · NCT07553663Exploratory Analysis of Enhanced Liver Function (ELF) Test to Detect Early Fatty Liver in High Risk Population
- Methodist Dallas Medical Center, Dallas
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ13 ሜይ 2026 · NCT06225193A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
- Pioneer Research Solutions, Houston
ተሳታዮችን በመፈለግ ላይደረጃ 1/2ጤናማ ተሳታዮች ይቀበላሉ
እድሜ ከ18 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ16 ኤፕሪ 2026 · NCT05648214NAFLD Clinical Care Pathway
- Michael E. DeBakey VA Medical Center, Houston, TX, Houston
ተሳታዮችን በመፈለግ ላይጤናማ ተሳታዮች ይቀበላሉ
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ14 ኖቬም 2025 · NCT06671886Evaluation of Non-Invasive Tests for Metabolic Liver Disease
- First Surgical Hospital, Bellaire
- Endeavor Clinical Trials, San Antonio
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
እድሜ ከ18 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ14 ኦገስ 2025 · NCT07122700ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ5 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።